Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters and the stock price to rise further.” Vertex has raised its revenue forecast for the full year 2025, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- RBC says Journavx review documents hint at focus in future chronic pain data
- Cautious Hold on Vertex Pharmaceuticals Amid Early-Stage Uncertainty of VX-522 Development
- Vertex Pharmaceuticals files automatic mixed securities shelf
- Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
- Vertex Pharmaceuticals: Strong Financial Performance and Promising Future Prospects Reinforce Buy Rating